Project Grant R21CA296713
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This $162,486 Project Grant, awarded by the National Cancer Institute (CFDA Program 93.398 - Cancer Research Manpower), supports research at Case Western Reserve University to study translation regulation and its role in glioblastoma (GBM) stem cell adaptation to hypoxic tumor environments. The research aims to use ribosome profiling and RNA sequencing to elucidate how translational regulation, rather than transcriptional regulation, enables GBM stem cells to survive and proliferate in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $231,413 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish in vitro models that reconstitute human testicular germ cell neoplasia in situ (GCNIS), the precursor to testicular cancers. The award aims to take advantage of recent advances in human germ cell biology to produce human primordial germ cell-like cells (PGCLCs) from induced...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $451,996 to the University of Texas at Arlington to develop a high-throughput screening platform for identifying novel therapies to target migrating and treatment-resistant glioblastoma (GBM) cells. The goal is to create an integrated ex vivo system that can reliably induce and screen for drugs that could eradicate or slow down these highly invasive and therapy-resistant brain cancer...
This Project Grant award of $1,064,642 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Tufts Medical Center to investigate the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling axis in regulating glioma stem cell (GSC) properties and glioblastoma (GBM) recurrence. The research aims to characterize how the ANG-PLXNB2-tRNA-derived small RNA (tiRNA) pathway maintains GSC stemness and contributes to therapeutic resistance, with the goal...
The National Cancer Institute (NCI) awarded a $415,257 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Methodist Hospital Research Institute (HMRI) in Houston, TX to develop a pre-clinical syngeneic pig glioma model for research and translational studies related to glioblastoma (GBM). The project aims to establish a large animal glioma model that can recapitulate key features of human GBM, which is a uniformly fatal brain cancer with poor prognosis. The model will be used to study...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $151,856 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the relationship between the hyper-thrombotic state and immunosuppression in glioblastoma (GBM), the most common primary malignant brain tumor. The research aims to: 1) investigate how GBM induces platelet hyperactivity and its impact on tumor growth, and 2)...
This Project Grant award of $404,972 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports research by the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate ribosome biogenesis and specialized translation in glioblastoma, the most aggressive form of brain cancer. The key objectives are to: 1) Identify differences in small nucleolar RNA (snoRNA) expression and rRNA modifications between glioma stem cells, astrocytes,...